About: covid:PMC7130468

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: covid:PMC7130468 Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Thing, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
Creator	Moorthy, Vasee Modjarrad, Kayvon Shao, Yiming Bavdekar, Ashish Cichutek, Klaus Cravioto, Alejandro Fritzell, Bernard Karron, Ruth Powell, Mair Smith, Peter Giersing, Birgitte Graham, Barney Kaslow, David Lanata, Claudio
is schema:about of	named entity 'Geneva' named entity 'Vaccines' named entity 'public private partnerships' named entity 'clinical trial' named entity 'neonatal herpes' named entity 'serotypes' named entity 'malaria vaccines' named entity 'WHO' named entity 'high income country' named entity 'MedImmune' named entity 'pathogen' named entity 'decision-making' named entity 'Infection' named entity 'NIBSC' named entity 'disease burden' named entity 'Middle Eastern Respiratory Syndrome' named entity 'Asia' named entity 'WHO' named entity 'neonatal period' named entity 'infection' named entity 'HSV-1' named entity 'human pathogens' named entity 'antibody' named entity 'paediatrics' named entity 'HSV-1' named entity 'influenza vaccine' named entity 'Glaxo SmithKline' named entity 'vaccine research' named entity 'research and development' named entity 'clinical studies' named entity 'vaccine' named entity 'disease burden' named entity 'HSV-1' named entity 'WHO' named entity 'High levels' named entity 'WHO' named entity 'National Institute for Biological Standards and Control' named entity 'preterm infants' named entity 'Phase III' named entity 'pharmaceutical company' named entity 'correlates of protection' named entity 'dengue' named entity 'immunisation' named entity 'Australasia' named entity 'decision-making' named entity 'initial infection' named entity 'translational research' named entity 'correlates of protection' named entity 'therapeutic vaccine' named entity 'clinical evaluation' named entity 'vaccine' named entity 'vaccine' named entity 'pathogens' named entity 'IgG' named entity 'WHO' named entity 'WHO' named entity 'reduction targets' named entity 'aetiology' named entity 'WHO' named entity 'Shigella' named entity 'HSV-2 infection' named entity 'public health' named entity 'HIV vaccines' named entity 'HSV-2' named entity 'vaccine' named entity 'disease burden' named entity 'vaccine' named entity 'pathogens' named entity 'serotypes' named entity 'recombinant' named entity 'product development' named entity 'HSV-1' named entity 'R&D' named entity 'infection' named entity 'protein' named entity 'vaccine' named entity 'vaccine' named entity 'vaccine' named entity 'WHO' named entity 'neutralising antibody' named entity 'WHO' named entity 'WHO' named entity 'WHO' named entity 'prophylaxis' named entity 'vaccine' named entity 'rheumatic heart disease'

Attributes

Values

Creator

Moorthy, Vasee
Modjarrad, Kayvon
Shao, Yiming
Bavdekar, Ashish
Cichutek, Klaus
Cravioto, Alejandro
Fritzell, Bernard
Karron, Ruth
Powell, Mair
Smith, Peter
Giersing, Birgitte
Graham, Barney
Kaslow, David
Lanata, Claudio

is schema:about of

named entity 'Geneva'
named entity 'Vaccines'
named entity 'public private partnerships'
named entity 'clinical trial'
named entity 'neonatal herpes'
named entity 'serotypes'
named entity 'malaria vaccines'
named entity 'WHO'
named entity 'high income country'
named entity 'MedImmune'
named entity 'pathogen'
named entity 'decision-making'
named entity 'Infection'
named entity 'NIBSC'
named entity 'disease burden'
named entity 'Middle Eastern Respiratory Syndrome'
named entity 'Asia'
named entity 'WHO'
named entity 'neonatal period'
named entity 'infection'
named entity 'HSV-1'
named entity 'human pathogens'
named entity 'antibody'
named entity 'paediatrics'
named entity 'HSV-1'
named entity 'influenza vaccine'
named entity 'Glaxo SmithKline'
named entity 'vaccine research'
named entity 'research and development'
named entity 'clinical studies'
named entity 'vaccine'
named entity 'disease burden'
named entity 'HSV-1'
named entity 'WHO'
named entity 'High levels'
named entity 'WHO'
named entity 'National Institute for Biological Standards and Control'
named entity 'preterm infants'
named entity 'Phase III'
named entity 'pharmaceutical company'
named entity 'correlates of protection'
named entity 'dengue'
named entity 'immunisation'
named entity 'Australasia'
named entity 'decision-making'
named entity 'initial infection'
named entity 'translational research'
named entity 'correlates of protection'
named entity 'therapeutic vaccine'
named entity 'clinical evaluation'
named entity 'vaccine'
named entity 'vaccine'
named entity 'pathogens'
named entity 'IgG'
named entity 'WHO'
named entity 'WHO'
named entity 'reduction targets'
named entity 'aetiology'
named entity 'WHO'
named entity 'Shigella'
named entity 'HSV-2 infection'
named entity 'public health'
named entity 'HIV vaccines'
named entity 'HSV-2'
named entity 'vaccine'
named entity 'disease burden'
named entity 'vaccine'
named entity 'pathogens'
named entity 'serotypes'
named entity 'recombinant'
named entity 'product development'
named entity 'HSV-1'
named entity 'R&D'
named entity 'infection'
named entity 'protein'
named entity 'vaccine'
named entity 'vaccine'
named entity 'vaccine'
named entity 'WHO'
named entity 'neutralising antibody'
named entity 'WHO'
named entity 'WHO'
named entity 'WHO'
named entity 'prophylaxis'
named entity 'vaccine'
named entity 'rheumatic heart disease'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software